| 项目编号 |
PRJCA019008 |
| 项目标题 |
Phosphoproteomic Characterization and Kinase Signature Predict AML Patients Response to Venetoclax plus 3+7 Daunorubicin and Cytarabine Chemotherapy |
| 涉及领域 |
Medical |
| 数据类型 |
proteome
|
| 物种名称 |
Homo sapiens
|
| 描述信息 |
Chemotherapy resistance remains a formidable obstacle in the therapeutic management of acute myeloid leukemia, necessitating the exploration of optimal strategies to augment therapeutic benefit.In a recent phase trial, we evaluated the DA plus V chemotherapy In a recent phase trial, we evaluated the DA plus V chemotherapy regimen in adult AML patients.To elucidate the underlying mechanistic determinants governing the response to DAV in AML, we adopted an exhaustive quantitative phosphoproteomics to discern distinct molecular signatures characterizing the subset of DAV-sensitive patients. |
| 样品范围 |
Multiisolate |
| 发布日期 |
2023-08-12 |
| 出版信息 |
| PubMed ID |
文章标题 |
杂志名称 |
Doi |
发表年份 |
| 38161214
|
Phosphoproteomic Characterization and Kinase Signature Predict Response to Venetoclax Plus 3+7 Chemotherapy in Acute Myeloid Leukemia
|
Advanced Science
|
10.1002/advs.202305885
|
2023
|
|
|
| 项目资金来源 |
| 机构 |
项目类型 |
授权项目ID |
授权项目名称 |
| Fundamental Research Funds for the Central Universities
|
|
226-2022-00003
|
|
|
|
| 提交者 |
Yinghui
Zhu (zhuyinghui1989@hotmail.com)
|
| 提交单位 |
Tongji University |
| 提交日期 |
2023-08-12 |
